|2.||Chronic Hepatitis C
|4.||Chronic Hepatitis B
|1.||Walker, Bruce D: 33 articles (01/2015 - 12/2002)|
|2.||Siliciano, Robert F: 25 articles (09/2014 - 04/2003)|
|3.||Busch, Michael P: 25 articles (03/2014 - 03/2003)|
|4.||Montefiori, David C: 24 articles (01/2014 - 03/2002)|
|5.||Deeks, Steven G: 22 articles (11/2015 - 02/2002)|
|6.||Mellors, John W: 20 articles (12/2015 - 04/2002)|
|7.||Chun, Tae-Wook: 19 articles (06/2015 - 06/2002)|
|8.||Fauci, Anthony S: 18 articles (07/2015 - 06/2002)|
|9.||Soriano, Vincent: 18 articles (08/2013 - 07/2003)|
|10.||Lifson, Jeffrey D: 16 articles (12/2015 - 02/2003)|
|1.||RNA (Ribonucleic Acid)IBA
09/01/2004 - "On the other hand, the pp67 RNA assay was highly specific and effective in pinpointing high viremia patients. "
08/01/2003 - "Nevertheless, from a viral perspective, the patient most likely to achieve a good outcome following OLT is someone with low-level (< or = 10(9) copies/mL) HCV RNA viremia both pre- and post-OLT and a genotype other than lb. "
01/01/2002 - "A rapid and marked decrease of HCV RNA viremia of more than 2 logs was observed in 10 (71%) of 14 patients at week 2 of treatment. "
08/01/2001 - "HBV/HCV coinfection was associated with lower HBV viremia (8.2 x 10(4) copies/mL) and lower HCV-RNA levels (7 x 10(5) IU/mL), than the corresponding control group (P <.05), with more marked decrease in HBV replication (P <.05). "
06/27/2006 - "DFPP appeared to be effective in reducing HCV viremia and preventing HCV recurrence in patients with high HCV RNA levels after LDLT. "
|2.||DNA (Deoxyribonucleic Acid)IBA
07/01/1999 - "This report provides strong evidence that HIV DNA levels in PBMCs correlate with therapeutic efficacy and suggests that DNA quantitation is a useful tool to monitor the decay of the HIV reservoir toward disease remission, especially when viremia is undetectable."
08/01/2013 - "Plasma viremia was detectable in 9 patients, whereas HIV-1 DNA was detectable in all 10 patients, indicating that HIV-1 had not been eliminated."
07/09/2015 - "This study demonstrated for the first time that TTSuV viremia can be controlled by a combined DNA and protein immunization, especially apparent two weeks after the first DNA immunization before seroconversion was observed. "
01/01/2014 - "The results from this study demonstrate that the PCV2 vaccine used in this study is effective at reducing PCV2 viremia and lymphoid PCV2 DNA, even for PCV2-viremic pigs with passively acquired MDA at the time of vaccination. "
08/01/2013 - "The aim of this study was to detect VZV viremia and quantify VZV DNA using quantitative polymerase chain reaction (qPCR) in blood from different populations. "
05/01/1987 - "The virus, first detected in the placenta during initial maternal viremia, replicated after the time when maternal blood was cleared of virus, although high titers of maternal serum antibodies were present. "
08/01/2011 - "Our findings provide the first report demonstrating that clearance of rotavirus antigenemia and possibly viremia are mediated by multiple effector lymphocyte subsets and serum antibodies."
08/01/2008 - "Maternal antibodies failed to provide protection against viremia in chicks at 21-25 DPH. "
01/01/2007 - "[Efficacy of absorbance ratio of ELISA antibodies [corrected] for hepatitis C virus of 3th generation in the prediction of viremia evaluated by PCR]."
11/01/2000 - "During follow-up (4.88 +/- 0.42 years), a group of these patients cleared their antibodies against the envelope protein E2 with (4 of 29 cases; 13.8%) or without (9 of 29 cases; 31%) the reappearance of viremia. "
03/19/2015 - "ACT led to in vivo antiviral immunity for up to 6 months with viral control, resulting in complete clearance of viremia in 86% of patients with antigen-specific T-cell responses. "
01/01/2015 - "Myd88(-/-) mice did not have a significant increase in the initial viremia, but substantial viral antigen persisted in the mice sera, a response similar to Rag2(-/-) mice, suggesting that the MyD88-dependent pathway participated in evoking an adaptive immune response against the clearance of intrahepatic HBV. "
08/01/2011 - "Real-time PCR is more sensitive and specific (earlier detection) than pp65 antigen test and it is a more reliable marker to monitor the clearance of viremia. "
09/01/1993 - "Five children whose tests results were negative for all four antigens did not have viremia or hepatic dysfunction; 13 of the 16 children with positive results for the four antigens had both viremia and hepatic dysfunction. "
03/01/1990 - "The SPA therapy neither reversed FeLV viremia nor resulted in consistent improvement in humoral immune responses to FeLV antigens. "
04/01/2013 - "We were able to observe that most patients who were treated with an interferon-based regime showed a significant reduction in delta viremia. "
03/01/1993 - "In a six month follow-up of the complete responders, clearance of viremia was observed in 90.3% at the end of interferon treatment and in 71.0% six months after the end of interferon treatment."
09/02/2011 - "Mice infected with the resistant strain (A156F [99.9%]) developed only low-level viremia and the virus was successfully eliminated with interferon therapy. "
11/15/2005 - "Sustained clearance of viremia was achieved in 38% of the patients treated with interferon, compared with 12% of untreated children (P<.05). "
02/01/1997 - "The rates for ALT normalization and clearance of hepatitis C virus (HCV) viremia at the end of the 24-week interferon therapy were similar for groups A and B (58% vs 60% and 55% vs 48%, respectively). "
|6.||Ganciclovir (Cytovene)FDA LinkGeneric
07/01/1993 - "We conclude that routine surveillance for CMV shedding, especially in blood and urine, can identify recipients at high risk of CMV disease, and propose a trial in which those with asymptomatic viremia are allocated to receive ganciclovir or placebo, in order to assess the efficacy of "preemptive" therapy in this group of patients."
01/01/2014 - "CMV viremia was successfully cleared with ganciclovir, and the patient experienced clinical and biochemical improvements. "
06/01/2000 - "The viremia was negative before the AGA in many patients, demonstrating the therapeutic efficacy of ganciclovir."
01/01/1998 - "In conclusion, the CMV antigenemia assay is effective in monitoring CMV viremia, and ganciclovir treatment should be done during early CMV viremia in OKT3-treated recipients."
12/01/2009 - "Historically, SOT recipients treated with short courses of ganciclovir, without documented clearance of viremia, had relapse rates of 23-33%. "
06/01/2015 - "Ideally, vaccines should stimulate complete immunity providing 100% protection against disease, viremias, shedding, and 100% fetal protection in vaccinates when challenged with a range of diverse antigenic viruses (subgenotypes). "
01/01/2015 - "Importantly, the control of SHIV viremia was significantly improved in animals from both Env-immunized groups relative to adjuvant alone controls, demonstrating the potential of AbISCO to act as a stand-alone adjuvant for Env-based vaccines. "
07/17/2015 - "Current commercial PCV2 vaccines are almost based on PCV2a and have been shown to be effective in reducing PCV2a and PCV2b viremia and PCV2-associated lesions and diseases. "
07/23/2014 - "Current commercial PCV2 vaccines are all based on PCV2a and have been shown to be effective in reducing PCV2a and PCV2b viremia and PCV2-associated lesions and disease. "
08/01/2008 - "Although the protective efficacy of these candidate vaccines has yet to be demonstrated, some vaccination regiments appear to dampen initial viremia and prolong disease-free survival. "
|8.||Lamivudine (3TC)FDA Link
06/01/2005 - "This finding may provide a rationale for the potential use of lamivudine for the treatment of pregnant women as a safe and effective measure to reduce the level of maternal viremia."
04/01/2007 - "The efficacy of antiviral HBV therapy is limited by the duration of lamivudine treatment: in 4 out of 5 patients with virologic response, the viremia condition relapsed several weeks after the medication had been stopped. "
03/01/2005 - "The rate of clearance of HBV viremia ranged between 67% and 100%, and the frequency of ALT normalization was between 50% and 100% with lamivudine use. "
05/01/2015 - "The aim of this study was to assess the long-term results and effectiveness of lamivudine in patients with low baseline viremia and early virological treatment response. "
06/01/2000 - "(-)FTC significantly reduced viremia and intrahepatic WHV replication in a dose-dependent manner that was comparable to the antiviral activity of lamivudine observed in previous studies conducted by our laboratories. "
|9.||Ribavirin (Virazole)FDA LinkGeneric
02/01/1999 - "In a group of previous IFN-alpha2a-treated chronic HCV patients we obtained a similar sustained clearance of viremia when retreated either with IFN-alpha2a alone or with a combination of IFN-alpha2a and ribavirin for 6 months. "
11/01/2001 - "After a basic course of 12 months (IFNalpha-2b 3 MU/3 times a week; Rb 3 x 200 mg/day), patients achieving clearance of viremia underwent maintenance therapy with ribavirin (3 x 200 mg/day). "
11/01/1996 - "While the addition of ribavirin did not result in further reductions in viremia in the following weeks on study treatment, 13 (81%) of the 16 patients had at least a -0.5 log10 change in viral titer at week 12. "
12/01/2014 - "Successful prevention of HCV transmission was noted in 1 recipient by pretreatment of the donor with peginterferon/ribavirin to undetectable levels of HCV viremia before stem cell harvest. "
03/20/2014 - "All the patients had HEV viremia when ribavirin was initiated (all 54 in whom genotyping was performed had HEV genotype 3). "
|10.||Interferon-alpha (Interferon Alfa)FDA Link
03/15/2002 - "Treatment with interferon-alpha produced a complete clinical remission and synchronous marked decreases in viremia and monoclonal B-cell prevalence. "
08/01/2009 - "HCV viremia was cleared under therapy with pegylated interferon-alpha in all 3 cases. "
11/01/2005 - "Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys."
07/01/2003 - "The aim of the present study in HCV-positive (HCV+) HD patients is to determine whether HD induces the production of interferon-alpha (IFN-alpha) and if such production can contribute to viremia reduction. "
04/01/2008 - "Human immunodeficiency virus viremia induces plasmacytoid dendritic cell activation in vivo and diminished alpha interferon production in vitro."
|1.||Highly Active Antiretroviral Therapy (HAART)
01/01/2007 - "Human immunodeficiency virus type 1 (HIV-1) infected children treated with highly active antiretroviral therapy (HAART) may develop a significant reduction of plasma viremia associated with an increase in CD4+ T-cell counts. "
03/18/2005 - "Antiviral therapy prolongs suppression of viral replication and allows for significant immune reconstitution but has not been effective in eradicating reservoirs of virus, which produce resurgent viremia when highly active antiretroviral therapy (HAART) is discontinued. "
02/01/2000 - "The results indicate that while HAART and HAART plus rIL-2 are both able to significantly reduce plasma viremia after 12 weeks of treatment, a significant reduction of the number of provirus-infected cells can be achieved only by treatment with HAART plus rIL-2."
01/01/2008 - "Although highly active antiretroviral therapy (HAART) is effective in reducing viremia, less is known about its effect on tissue compartments. "
01/01/2014 - "Our findings suggest that cumulative viremia should be explored further as a tool to simultaneously evaluate the individual and public health efficacy of HAART. "
10/01/2008 - "Pre-transplant seropositivity did not protect against sustained viremia and the antibody response was not associated with clearance of the virus."
09/01/2010 - "Monitoring and pre-emptive of immunosuppression reduction were associated with resolution of viremia and showed effective in BKVAN recipients at the early stage without acute rejection or graft loss. "
01/01/2006 - "We conclude delaying pre-emptive therapy with ODG until whole blood QPCR> or =10 000 copies/ml is a safe and effective strategy for CMV viremia after allogeneic stem cell transplant in clinically stable patients."
09/01/2015 - "Of 17 patients treated with transplant donor (n = 16) or third-party (n = 1) CMVpp65CTLs, 15 cleared viremia, including 3 of 5 with overt disease. "
03/01/2013 - "This intervention allows for expanding BKV-specific cellular immune responses, curtailing of BKV replication in the graft, and clearance of BKV viremia in 70-90% patients. "
|3.||Transplantation (Transplant Recipients)
12/15/2009 - "In contrast, after transplantation, reconstitution of CMV-LPA was significantly associated with absence of CMV viremia over 360 days of follow-up (P = .04) and with faster clearance of viremia during individual episodes of CMV reactivation (P = .03). "
04/01/2015 - "The serial monitoring of BK viremia in kidney transplant recipients was helpful in predicting BKVAN and might prevent further progression."
01/01/2015 - "All BKVAN patients (n = 7, 3.1%) cleared viremia with a mean time of 5.9 months (range 1-15 months) and manifested no decline in estimated glomerular filtration rate from 1 month to 5 years after transplantation. "
05/20/2010 - "Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis."
12/15/2009 - "The strongest immune correlates with protection against CMV viremia in hematopoietic stem cell transplant recipients are reconstitution of CMV-specific T cell memory responses (LPA) and recovery of natural killer cell function. "
12/15/2011 - "Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia."
07/01/1997 - "We retrospectively analyzed 105 paired liver biopsy specimens taken before and after treatment from 93 patients who persistently showed biochemical remission and an absence of viremia for up to 68 months. "
10/01/2009 - "in our study, a reduction in viremia > or = 2 logs 2 weeks after treatment could ensure SVR. "
11/01/2014 - "Absence of Detectible HIV-1 Viremia After Treatment Cessation in an Infant."
11/07/2013 - "Absence of detectable HIV-1 viremia after treatment cessation in an infant."
|5.||Drug Therapy (Chemotherapy)
05/01/1990 - "A marked effect was observed on virus replication in the respiratory tract when chemotherapy was commenced 1 day before virus inoculation; it also cleared the viremia and reversed the progression of clinical signs. "
08/01/1999 - "This combined chemotherapy/ therapeutic vaccination regimen induced a significant reduction in the steady-state level of viremia in one out of two chronically infected rhesus macaques. "
08/01/1987 - "Viremia cleared during drug therapy in 88 percent of patients. "
05/01/2015 - "Overall, 19% of the respondents declared never having treated an immunotolerant patient; 81% reported that they had treated such patients under some circumstances: 73% before immunosuppression or chemotherapy, 54% treated pregnant women in their third trimester when viremia was greater than 7 log IU/ml, 49% treated health professionals to prevent contamination, and 31% before medically assisted procreation. "
11/18/2010 - "Patients with CMV disease or viremia refractory to antiviral chemotherapy or both were eligible for adoptive T-cell transfer and received a mean of 21 × 10³/kg pp65-specific T cells. "